IN8bio at Sidoti Small-Cap Virtual Conference: gamma-delta push

IN8bio, a biotech company focused on developing therapies based on gamma-delta T cells, recently addressed a two-pronged strategy at the Sidoti Small-Cap Virtual Conference. The company aims to leverage these unique immune cells for treating autoimmune diseases and glioblastoma. IN8bio highlighted promising early data from its lead autoimmune program, INB-619, which demonstrated strong in vitro B-cell killing with no IL-6 secretion, a marker associated with cytokine release syndrome.

In the glioblastoma program, the company reported a median progression-free survival of 13 months, up from 6.6 months, and a median overall survival of 19.5 months, up from 13.2 months. The company raised over $20 million in December 2025 and anticipates a second close of approximately $20 million, which could support operations until the IND submission.

IN8bio's CEO, Will, emphasized the company's commitment to developing more precise treatments using gamma-delta T cells, which it believes can act as both direct attackers and coordinators of the immune response.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.